期刊文献+

艾滋病生物治疗研究进展 被引量:1

Current development of biological therapy in AIDS
原文传递
导出
摘要 HAART能有效抑制艾滋病患者体内的病毒复制,但不能根除患者体内病毒,达到完全免疫重建,故有必要引入新的治疗策略,生物治疗就是其中之一。此文就生物治疗在艾滋病的研究进展作了综述。 Highly active antiretroviral therapy (HAART) has provided an effective means to suppress viral replication. However, HAART is unable to reconstitute HIV-specific immunity and eradicate the virus. These caveats with HAART support the rationale to develop novel approaches to treat the disease, including biological therapy. In this review, a brief introduction to current research of biological therapies in HIV/AIDS is given.
出处 《国际流行病学传染病学杂志》 CAS 2010年第5期343-346,共4页 International Journal of Epidemiology and Infectious Disease
关键词 获得性免疫缺陷综合征 高效抗逆转录病毒治疗 疫苗 Acquired immunodeficiency syndrome Highly active antiretroviral therapy Vaccine
  • 相关文献

参考文献25

  • 1Ye P,Kirschner DE,Kourtis AP.The thymus during HIV disease:role in pathogenesis and in immune recovery.Curr HIV Res,2004,2(2):177-183.
  • 2Boyman O,Purton JF,Surh CD,et al.Cytokines and T-cell homeostasis.Curr Opin Immunol,2007,19(3):320-326.
  • 3Long SA,Buckner JH.Combination of rapamycin and IL-2 increases de novo induction of human CD4(+)CD25(+)FoxP3(+) T cells.J Autoimmun,2008,30(4):293-302.
  • 4Marchetti G,Franzetti F,Gori A.Partial immune reconstitution following highly active antiretroviral therapy:can adjuvant interleukin2 fill the gap? J Antimicrob Chemother,2005,55(4):401-409.
  • 5Mitsuyasu R,Gelman R,Cherng DW,et al.The virologic,immunologic,and clinical effects of interleukin 2 with potent antiretroviral therapy in patients with moderately advanced human immunodeficiency virus infection:a randomized controlled clinical trial-AIDS Clinical Trials Group 328.Arch Intern Med,2007,167(6):597-605.
  • 6Molina JM,Levy Y,Fournier I,et al.Interleukin-2 before antiretroviral therapy in patients with HIV infection:a randomized trial (ANRS 119).J Infect Dis,2009,200(2):206-215.
  • 7Levy Y,Durier C,Krzysiek R,et al.Effects of interleukin-2 therapy combined with highly active antiretroviral therapy on immune restoration in HIV-1 infection:a randomized controlled trial.AIDS,2003,17(3):343-351.
  • 8Katlama C,Caaelain G,Duvivier C,et al.Interleukin-2 accelerates CD4 cell reconstitution in HIV-infected patients with severe immunosuppression despite highly active antiretroviral therapy:the ILSTIM study-ANRS 082.AIDS,2002,16(15):2027-2034.
  • 9Sellier P,Lafuente-Lafuente C,Bergmann JF.Interleukin-2 therapy in patients with HIV infection.N Engl J Med,2010,362(3):270-271.
  • 10Nacsa J,Edghill-Smith Y,Tsai WP,et al.Contrasting effects of low-dose IL-2 on vaccine-boosted simian immunodeficiency virus (SIV)-specific CD4+ and CD8+ T cells in macaques chronically infected with SIVmac251.J Immunol,2005,174(4):1913-1921.

同被引文献22

  • 1Michienzi A,Li S,Zaia JA,et al.A nucleolar TAR decoy inhibitor of HIV-1 replication[J].Proc Natl Acad Sci USA,2002,99(22):14047-14052.
  • 2Food and Drug Administration.Drug used in the treatment of HIV infection[EB/OL].(2007-11-25).http://www.fda.gov/oashi/aids/virals.html.
  • 3U.S.Food and Drug Administration.Drug used in the treatment of HIV infection[EB/OL].(2006-02-02).http://www.fda.gov/oashi/aids/virals.html.
  • 4De Clercq E.Antiviral drugs[J].Curr Opin Pharr,2010,10 (5):507-515.
  • 5Basavapathruni A,Anderson KS.Reverse transcription of the HIV-1 pandemic[J].FASEB,2007,21 (14):3795-3808.
  • 6Flexner C.HIV drug development:the next 25 years[J].Nat Rev Drug Discov,2007,6(12):959-966.
  • 7Busse KH,Penzak SR.Daruravir:a second-generation protease inhibitor[J].Am J Health Syst Pharm,2007,64(15):1593-1602.
  • 8Sax PE.FDA approval:maraviroc[J].AIDS Clin Care,2007,19(9):75.
  • 9Fadel H,Temesgen Z.Maraviroc[J].Drugs today(Barc),2007,43(11):749-758.
  • 10Evering TH,Markowitz M.Raltegravir(MK-0518):an integrase inhibitor for the treatment of HIV-1[J].Drugs today(Barc),2007,43(12):865-877.

引证文献1

二级引证文献2

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部